Research programme: cardiovascular and metabolic disorder therapeutics - Zealand Pharma/Boehringer Ingelheim

Drug Profile

Research programme: cardiovascular and metabolic disorder therapeutics - Zealand Pharma/Boehringer Ingelheim

Alternative Names: GLP-1/GLP-2 dual agonist - Zealand Pharma; glucagon/GLP-1 agonists; ZP GG 72

Latest Information Update: 30 Jul 2014

Price : $50

At a glance

  • Originator Zealand Pharma
  • Developer Boehringer Ingelheim; Zealand Pharma
  • Class Antihyperglycaemics; Obesity therapies; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Metabolic disorders; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2014 Preclinical trials in Cardiovascular disorders and Metabolic disorders in Denmark and Germany (unspecified route)
  • 20 Jun 2014 Preclinical pharmacodynamics data in Type-2 diabetes mellitus released by Zealand Pharma
  • 20 Jan 2014 Preclinical development is ongoing in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top